NCT07072169View on ClinicalTrials.gov

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

PHASE1RecruitingINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

May 31, 2027

Conditions

B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

ABO2203 Injection

SC or IV

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER